{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:37:45Z","timestamp":1781649465664,"version":"3.54.5"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.7759\/cureus.107121","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:20:43Z","timestamp":1776298843000},"source":"Crossref","is-referenced-by-count":1,"title":["Rapid Remission of Steroid-Refractory IgA Nephropathy With Targeted-Release Budesonide: A Case Report"],"prefix":"10.7759","author":[{"given":"Paola A","family":"Manrique-Pizarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m BC","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al.. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017, 389:2117-27. 10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette RA","year":"2023","unstructured":"Lafayette RA, Kristensen J, Stone A, et al.. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023, 402:859-70. 10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000381508","article-title":"The treatment of IgA nephropathy","volume":"1","author":"Lai KN","year":"2015","unstructured":"Lai KN, Leung JC, Tang SC. The treatment of IgA nephropathy. Kidney Dis (Basel). 2015, 1:19-26. 10.1159\/000381508","journal-title":"Kidney Dis (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi H","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al.. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017, 91:1014-21. 10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin BH","year":"2025","unstructured":"Rovin BH, Barratt J, Cook HT, et al.. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025, 108:S1-S71. 10.1016\/j.kint.2025.04.004","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465135-rapid-remission-of-steroid-refractory-iga-nephropathy-with-targeted-release-budesonide-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:20:43Z","timestamp":1776298843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465135-rapid-remission-of-steroid-refractory-iga-nephropathy-with-targeted-release-budesonide-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.107121","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}